Charles River Laboratories International, Inc. CRL NYSE

Charles River Laboratories International, Inc. (CRL) has shown declining revenue growth over the past 3 years, expanding from $4.1B to $4.0B (average -0.9%/yr). The company reported a net loss of $144M in its most recent fiscal year, with earnings trending at -533.2%/yr. The net profit margin is -3.6%, which is negative. the company was profitable in 3 out of the last 4 years tracked. The gross margin is 30.5% (moderate), with a -5.9pp trend over the period. With a $9B market cap and MOAT composite score of 45/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (15/100, Fail) — revenue or earnings are not growing
• PAST (75/100, Partial) — profitability has been inconsistent. Looking at the full 43-year history, the company was profitable in 35 of 43 years — a solid long-term record with occasional losses
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (45/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 48/100 with 2/7 criteria passed.